Nuclera

Bring rapid protein access to your benchtop with eProtein Discovery

Founded 2013

Cambridge, United Kingdom 108 employees Series C Total: $207.83M Biotechnology, Life Sciences +1

General Information

Company Name Nuclera

Founded Year 2013

Location

Cambridge, United Kingdom

Founders / Decision Makers

Employees 108

Industries Biotechnology, Life Sciences, Pharmaceutical

Funding Stage Series C

Business Model B2B, SaaS, D2C

Revenue Model Product Sales, Usage Based, Service Fee

Offices as of Oct 2026

Cambridge, United Kingdom Billerica, United States

Social

BounceWatch is an independent company data service, not affiliated with Nuclera. To contact Nuclera, visit nuclera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nuclera compare?

A PDF of Nuclera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nuclera soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Major Customer Win Oct 21, 2026

Bayer Crop Science provided insights on how Nuclera's eProtein Discovery™ membrane protein workflow helped them recover difficult membrane protein targets.

In The News Oct 16, 2026

Featured on Business Weekly: From Cambridge PhD startup to global biotech: inside Nuclera’s $87m growth strat...

Event Participation Oct 12, 2026

Nuclera is participating in ELRIG Drug Discovery 2026 in London, presenting a talk and two posters, and showcasing their eProtein Discovery™ System at booth H09.

Actively Hiring Oct 09, 2026

Hiring for 3 positions in the last 30 days.

Award Received Oct 02, 2026

Nuclera ranked 13th on the 2026 Sifted 250 Leaderboard, recognizing it among Europe's fastest-growing startups and scaleups.

Get alerts when Nuclera shows new signals

About Nuclera

Nuclera, founded in 2013 by PhD students at the University of Cambridge, has positioned itself as a transformative player in the biotechnology, life sciences, and pharmaceutical industries. With its headquarters in the United Kingdom and a burgeoning presence in Boston, MA, the company employs over 100 professionals dedicated to advancing protein science.

Capitalizing on its pioneering eProtein Discovery™ technology, Nuclera revolutionizes how researchers access and screen proteins through innovative, cell-free expression systems and digital microfluidics. This system enables rapid, in-house multiplex protein screening, even for challenging membrane proteins, which accelerates scientific discovery and breakthroughs in human health.

In its latest funding round on 01 January 2026, Nuclera secured a $12.00M Series C investment led by Elevage Medical Technologies, with participation from British Business Bank, Jonathan Milner, and GK Goh Financial Services. This investment underscores strong confidence in Nuclera's potential to make protein access routine and propel scientific innovation forward.

Business keywords: protein science, multiplex protein screening, cell-free expression systems, digital microfluidics, protein characterization, drug discovery, membrane proteins, biotech innovation, research acceleration, protein optimization, lab automation, protein synthesis, biotech startup, scientific research tools, rapid protein prototyping

Services & Products

eProtein Discovery System

Antibody Screening Services

Protein Design and Expression

Membrane Protein Production

Target Customers

Biotechnologists Pharmaceutical Researchers Drug Discovery Scientists Structural Biologists Academic Research Institutions

Funding Rounds & Investors (9)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$12.00M	4	Elevage Medical Technologies, British Business Bank +2	01 Jan 2026
Growth Equity VC	£51.50M	-		01 Oct 2025
Series C	$75.00M	10	Verve Ventures, Cambridge Innovation Capital +8	01 Oct 2024
Grant	£1.10M	1	Innovate UK	01 Jun 2024
Series B	$15.50M	2	Verve Ventures, Jonathan Milner	01 Jul 2022
Series B	$42.50M	7	Amadeus Capital Partners, Future Planet Capital +5	01 Feb 2022
Late VC	$10.00M	-		01 Dec 2018
Grant	£200.00K	-		01 Apr 2015
Grant	£30.00K	-		01 Jun 2014

Latest News

View All

From Cambridge PhD startup to global biotech: inside Nuclera’s $87m growth strategy

Business Weekly Oct 16, 2026

Nuclera appoints Carl Raimond as CEO

PMLiVE Oct 05, 2026

Nuclera: Carl Raimond

Healthinvestor.co.uk Sep 23, 2026

Nuclera appoints Carl Raimond as Chief Executive Officer

Cambridge Network Sep 22, 2026

Swiss BioTech startup ALP Bio raises €1.9 million to advance immune organoid and AI platform

Eu-startups Apr 30, 2026

New platform to accelerate drug discovery in Taiwan

Labmate-online.com Jan 22, 2026

Nuclera Alternatives & Competitors

View All Alternatives

Nuclera vs

LabFellows United States

Do More Science.

Seed

4 employees

Biotechnology, Life Sciences

Compare Nuclera vs LabFellows

Nuclera vs

Twist Bioscience United States

Synthetic DNA for Health & Sustainability

IPO

1317 employees

Biotechnology, Health Care

Compare Nuclera vs Twist Bioscience

Nuclera vs

LabTwin Germany

LabTwin is the leading voice powered digital lab assistant making research faster, easier and more e...

Acquired

9 employees

AI, Big Data

View all alternatives

FAQ About Nuclera

Bring rapid protein access to your benchtop with eProtein Discovery

Nuclera was founded in 2013.

Nuclera is headquartered in Cambridge, United Kingdom. As of Oct 2026, it also has offices in Billerica, United States.

Nuclera operates in Biotechnology, Life Sciences and Pharmaceutical. Its work centres on protein science, multiplex protein screening, cell-free expression systems and digital microfluidics. Its customers include Biotechnologists, Pharmaceutical Researchers and Drug Discovery Scientists.

Nuclera has a B2B, SaaS and D2C business model. Its revenue comes from Product Sales, Usage Based and Service Fee.

Nuclera has approximately 108 employees.

Nuclera has completed 9 funding rounds, raising a total of $207.83M. The latest funding stage is Series C.

Nuclera offers: eProtein Discovery System, Antibody Screening Services, Protein Design and Expression, Membrane Protein Production.

Top alternatives and competitors to Nuclera include LabFellows, Twist Bioscience, LabTwin, KAICO Ltd., Future Fields. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Nuclera and LabFellows are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nuclera, https://bouncewatch.com/company/nuclera, updated 13 October 2026. When citing, please name BounceWatch and link this page.

Nuclera

General Information

Discover More

What changed at Nuclera recently?

About Nuclera

Services & Products

Target Customers

Funding Rounds & Investors (9)

Latest News

Nuclera Alternatives & Competitors

FAQ About Nuclera